Drug intelligence / Profile preview

NB006

Development stage: Preclinical
Lead developer: Ningbo Newbay Medical Technology
Modality: Small Molecules

Overview

NB006 is a small molecule drug candidate currently in the preclinical stage of development by Ningbo Newbay Medical Technology (Newbay Pharma). It is being investigated for the treatment of advanced solid tumors. While the specific mechanism of action and molecular target have not been publicly revealed, the compound is part of a pipeline focused on precision oncology and targeted small molecules. As of early 2024, it remains in the early stages of research and development.

Beyond the preview

Go deeper on NB006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB006.

Explore the full profile